Bevacizumab reverses cerebral radiation necrosis.
Wong
Eric T
ET
Brain Tumor Center & Neuro-Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Huberman
Mark
M
Lu
Xing-Qi
XQ
Mahadevan
Anand
A
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001921:Brain / Q000528:radiation effects*; D001930:Brain Injuries / Q000188:drug therapy*; D002277:Carcinoma / Q000150:complications / Q000532:radiotherapy*; D005260:Female; D034381:Hearing Loss; D006801:Humans; D008279:Magnetic Resonance Imaging; D009303:Nasopharyngeal Neoplasms / Q000150:complications / Q000532:radiotherapy*; D009336:Necrosis / Q000188:drug therapy*; D011832:Radiation Injuries / Q000188:drug therapy*; D050397:Radiotherapy, Intensity-Modulated; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab